Indrayani Biotec

Who are in the management team of Indrayani Biotec?

As of March 2023, the management team of Indrayani Biotec includes Executive Director Kasiraman Sayee Sundar, Whole-time Directors Singarababu Indirakumar, Muthu Krishnan Ramesh, and G Swaminathan, along with independent and non-executive directors, including Chairman N M Ranganathan. The team oversees the company's governance and management.

As of March 2023, the management team of Indrayani Biotec includes the following members:<BR><BR>1. Kasiraman Sayee Sundar - Executive Director / Managing Director / Promoter<BR>2. Singarababu Indirakumar - Whole-time Director<BR>3. Muthu Krishnan Ramesh - Whole-time Director<BR>4. G Swaminathan - Whole-time Director<BR>5. K S Vaidyanathan - Independent Non-Executive Director<BR>6. N M Ranganathan - Chairman & Independent Director<BR>7. B N Padmaja Priyadarshini - Independent Non-Executive Director<BR>8. Lakshmi Prabha - Non-Executive & Non-Independent Director<BR>9. Rajesh Kumar - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive, non-executive, and independent directors, with various roles contributing to the governance and management of the company.

What does Indrayani Biotec do?

Indrayani Biotech Ltd is a micro-cap company specializing in cut flowers, strawberries, tissue culture plantlets, and hybrid vegetable seeds. As of December 2024, it reported net sales of 17 Cr and a market cap of Rs 72 Cr.

Overview: <BR>Indrayani Biotech Ltd is a micro-cap company in the Other Agricultural Products industry, specializing in the production of cut flowers, strawberries, tissue culture plantlets, and hybrid vegetable seeds.<BR><BR>History: <BR>Indrayani Biotech Limited was incorporated in 1992 and went public in 1994 to partially finance its projects. The latest quarterly results reported net sales and net profit for December 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 17 Cr (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Dec 2024) <BR>Market-cap value: Rs 72 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 12.00 <BR>Industry P/E: 12 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.30 <BR>Return on Equity: 9.40% <BR>Price to Book: 0.98 <BR><BR>Contact Details: <BR>Address: 1133/5 F C Road, Opp Police Grounds Pune Maharashtra : 411016 <BR>Tel: 91-20-25662021 <BR>Email: info@indrayani.com <BR>Website: http://www.indrayani.com

Has Indrayani Biotec declared dividend?

No Dividend History Available

Who are the peers of the Indrayani Biotec?

Indrayani Biotec's peers include L T Foods, KRBL, Kaveri Seed Co., and others, with varying management and growth risks. Indrayani Biotec has Below Average management risk and Excellent growth but the lowest 1-year return at -64.90% among its peers.

Peers: The peers of Indrayani Biotec are L T Foods, KRBL, Kaveri Seed Co., Guj. Ambuja Exp, GRM Overseas, Nag. Agri Tech., Annvrridhhi Ven, Flex Foods, and Universal Starch.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kaveri Seed Co., while Good management risk is found at L T Foods and Vishwas Agri. Average management risk is present at KRBL, Guj. Ambuja Exp, Flex Foods, and Universal Starch, while Below Average management risk is noted at Indrayani Biotec, GRM Overseas, Nag. Agri Tech., Annvrridhhi Ven. In terms of growth, Excellent growth is seen at Kaveri Seed Co., Good growth at L T Foods and Annvrridhhi Ven, while Below Average growth is noted at KRBL, Guj. Ambuja Exp, GRM Overseas, Nag. Agri Tech., Flex Foods, and Universal Starch. Indrayani Biotec has Excellent growth but Below Average management risk. Capital Structure ratings are Excellent for Kaveri Seed Co. and KRBL, Good for L T Foods, and Below Average for Indrayani Biotec, GRM Overseas, Nag. Agri Tech., Flex Foods, and Universal Starch.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Nag. Agri Tech. at 382.06%, while Indrayani Biotec has the lowest at -64.90%. This indicates that Indrayani Biotec's performance is significantly worse than its peers. Additionally, the six-month return is negative for Indrayani Biotec, Annvrridhhi Ven, Flex Foods, and Universal Starch.

What is the technical trend for Indrayani Biotec?

As of June 5, 2025, Indrayani Biotec's technical trend is bearish with moderate strength, supported by bearish Bollinger Bands and daily moving averages, despite some conflicting signals from the MACD and KST indicators.

As of 5 June 2025, the technical trend for Indrayani Biotec has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD indicates a mildly bullish signal, but the monthly MACD is bearish, which reflects a conflicting trend. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages also confirm a bearish trend. The KST shows a mildly bullish signal on the weekly chart but is bearish monthly, while Dow Theory indicates a mildly bullish stance weekly with no trend monthly. Overall, the indicators suggest a prevailing bearish sentiment, particularly in the longer time frames.

Who are the top shareholders of the Indrayani Biotec?

The top shareholders of Indrayani Biotec are G Swaminathan, the promoter with 9.09% ownership, and Jayaseelan Singaravelu, the highest public shareholder with 10.11%. Approximately 46.64% of shares are held by individual investors, with no mutual funds or foreign institutional investors involved.

The top shareholders of Indrayani Biotec include G Swaminathan, who is the promoter with the highest holding at 9.09%. Additionally, the highest public shareholder is Jayaseelan Singaravelu, holding 10.11%. The majority of the company's shares, approximately 46.64%, are held by individual investors. It's also noteworthy that there are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Indrayani Biotec?

As of 24th July, Indrayani Biotech Ltd has a market capitalization of 73.00 Cr and reported net sales of 130.23 Cr with a net loss of 3.50 Cr over the latest four quarters; specific values for Shareholder's Funds and Total Assets are unavailable.

As of 24th July, Indrayani Biotech Ltd has a market capitalization of 73.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 130.23 Cr. However, it experienced a net loss of 3.50 Cr during the same period.<BR><BR>The reporting period for the balance sheet is the latest annual period. Unfortunately, specific values for Shareholder's Funds and Total Assets are not available.

When is the next results date for Indrayani Biotec?

Indrayani Biotec will announce its results on 14 August 2025.

Indrayani Biotec will declare its results on 14 August 2025.

Is Indrayani Biotec overvalued or undervalued?

As of August 18, 2025, Indrayani Biotec is considered overvalued and risky due to its negative PE ratio of -8.57, high EV to EBITDA ratio of 22.74, and a year-to-date stock return of -63.91%, especially when compared to its peers.

As of 18 August 2025, the valuation grade for Indrayani Biotec has moved from attractive to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued based on its current metrics, particularly given its negative PE ratio of -8.57 and an EV to EBIT ratio of -21.70, which are alarming indicators of financial distress. Additionally, the EV to EBITDA ratio stands at 22.74, suggesting that the market is pricing the company at a premium despite its poor earnings performance.<BR><BR>In comparison to its peers, Indrayani Biotec's valuation metrics are starkly unfavorable. For instance, Elegant Floricul is categorized as very expensive with a PE ratio of 18.24, while Trescon also falls into the very expensive category with an EV to EBITDA of -209.83. This stark contrast highlights the challenges faced by Indrayani Biotec, especially with a year-to-date stock return of -63.91% compared to a modest 4.01% return for the Sensex. Overall, the company is deemed overvalued given its current financial ratios and performance relative to its peers.

How has been the historical performance of Indrayani Biotec?

Indrayani Biotec's historical performance has been volatile, with net sales declining from 166.23 Cr in March 2024 to 130.23 Cr in March 2025, resulting in significant losses, including a profit after tax of -6.11 Cr in March 2025 compared to 10.42 Cr the previous year. The company's earnings per share also fell from 1.4 to -1.34 during this period.

Answer:<BR>The historical performance of Indrayani Biotec has shown significant fluctuations over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Indrayani Biotec's net sales peaked at 166.23 Cr in March 2024 but fell to 130.23 Cr by March 2025. The total operating income followed a similar trend, decreasing from 166.23 Cr in March 2024 to 130.23 Cr in March 2025. The company experienced a notable increase in raw material costs, which reached 82.77 Cr in March 2025, down from 97.13 Cr in March 2024. Operating profit (PBDIT) also declined from 24.66 Cr in March 2024 to 18.36 Cr in March 2025, while profit before tax turned negative at -5.74 Cr in March 2025 after being positive at 10.97 Cr in March 2024. Consequently, the profit after tax also fell to -6.11 Cr in March 2025 from 10.42 Cr in March 2024. The earnings per share (EPS) reflected this downturn, dropping to -1.34 in March 2025 from 1.4 in March 2024. Overall, the company's financial performance has been inconsistent, with significant losses in the most recent fiscal year following a period of profitability.

Are Indrayani Biotec latest results good or bad?

Indrayani Biotech's latest results show a significant sequential profit increase and revenue growth, but declining operating margins and year-on-year profit decline raise concerns about its financial health, leading to a "Strong Sell" rating. Overall, the results indicate more distress than recovery.

Indrayani Biotech's latest results present a mixed picture. On one hand, the company reported a net profit of ₹0.91 crore for Q2 FY26, which is a significant sequential improvement of 468.75% from the previous quarter. Additionally, revenue increased by 23.54% quarter-on-quarter and 16.68% year-on-year, indicating some positive momentum in sales.<BR><BR>However, these gains are overshadowed by concerning trends in profitability and operational efficiency. The operating margin has drastically declined from 23.76% in the same quarter last year to just 6.82% this year, reflecting severe margin compression. Furthermore, the net profit shows a year-on-year decline of 25.41%, suggesting that while the company is generating more revenue, it is struggling to convert that into sustainable profit.<BR><BR>The overall financial health of Indrayani Biotech is under scrutiny due to high leverage, negative cash flows, and a lack of institutional investor confidence. The company's rating has dropped to "Strong Sell," indicating significant concerns about its operational viability despite the recent profit recovery. <BR><BR>In summary, while there are some positive signs in terms of revenue growth, the underlying operational challenges and declining margins suggest that the results are more indicative of a company in distress rather than a robust recovery.

Should I buy, sell or hold Indrayani Biotec?

Which are the latest news on Indrayani Biotec?

Why is Indrayani Biotech Ltd falling/rising?

As of 18-Jan, Indrayani Biotech Ltd's stock price is rising to Rs. 9.67 after a trend reversal, but it has faced significant challenges with a year-to-date decline of 14.50% and a dramatic 71.73% drop over the last year, indicating weak fundamentals and reduced investor interest.

As of 18-Jan, Indrayani Biotech Ltd's stock price is rising, currently at Rs. 9.67, reflecting a change of 0.25 (2.65%) upward. This increase follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. Despite this recent uptick, the stock has faced significant challenges, including a new 52-week low of Rs. 9.12 hit earlier in the day.<BR><BR>Over the past week, the stock has experienced a decline of 4.82%, and its performance over the last month shows a substantial drop of 28.42%. Year-to-date, the stock is down 14.50%, and it has dramatically underperformed over the last year with a decline of 71.73%. This consistent underperformance is compounded by the company's weak long-term fundamentals, including a staggering -242.96% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 17.89 times, indicating low ability to service debt.<BR><BR>Investor participation has also been falling, with a delivery volume decrease of 37.66% against the 5-day average, suggesting reduced interest from shareholders. Furthermore, the stock is trading below all its moving averages, which typically signals a bearish trend. Despite the recent rise, the overall outlook remains cautious due to the company's negative financial results over the last six quarters and its consistent underperformance against benchmarks.